Skip to main content

Rockwell Medical Value Stock - Dividend - Research Selection

Rockwell medical

ISIN: US7743741024 , WKN: 916118

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Rockwell Medical, Inc. operates as an integrated biopharmaceutical company targeting end-stage renal and chronic kidney diseases in the United States and internationally. The company\'s lead drug includes Triferic, an iron maintenance therapy that replaces the iron lost by patients during hemodialysis treatment. It also provides Calcitriol, a generic active vitamin D injection, which is indicated for the treatment of secondary hyperparathyroidism in dialysis patients. In addition, the company manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, Renalpure powder bicarbonate concentrate, and SteriLyte liquid bicarbonate concentrate; and ancillary products, including blood tubings, fistula needles, specialized custom kits, dressings, cleaning agents, filtration salts, and other supplies used by hemodialysis providers. Its concentrated dialysate products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient\'s bloodstream. Rockwell Medical, Inc. sells its products directly, as well as through independent sales agents and distributors. The company\'s target customers include senior and operating management of dialysis companies, dialysis service providers, nephrologists, clinic administrators, nurses, medical directors, and technical and purchasing personnel. Rockwell Medical, Inc. was founded in 1995 and is based in Wixom, Michigan.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Rockwell Medical, Inc. 2026 Q2 - Results - Earnings Call Presentation

2026-08-17
2026-08-17. The following slide deck was published by Rockwell Medical, Inc.

Rockwell Medical, Inc. (RMTI) Q2 2026 Earnings Call Transcript

2026-08-13
Rockwell Medical, Inc. (RMTI) Q2 2026 Earnings Call August 13, 2026 8:00 AM EDTCompany ParticipantsHeather Hunter - Senior VP & COOMark Strobeck -...

Rockwell Medical Q2 Adj. EPS $(0.04) Beats $(0.23) Estimate, Sales $17.780M Miss $17.837M Estimate

2026-08-13
Rockwell Medical (NASDAQ:RMTI) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.23) by 82.61 percent. This is a 300 percent decrease over losses of $(0.01) per share from

Rockwell Medical Affirms FY2026 Sales Guidance of $70.000M-$75.000M vs $72.469M Est

2026-08-13
Rockwell Medical (NASDAQ:RMTI) affirms FY2026 sales outlook from $70.000 million-$75.000 million to $70.000 million-$75.000 million vs $72.469 million estimate.

Rockwell Medical Stock Keeps Nasdaq Listing After Compliance Notice

2026-07-20
Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today

HC Wainwright & Co. Maintains Buy on Rockwell Medical, Raises Price Target to $20

2026-07-09
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Rockwell Medical (NASDAQ:RMTI) with a Buy and raises the price target from $2 to $20.

Rockwell Medical Plans 1-for-10 Reverse Stock Split Next Week

2026-06-29
Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today